Spots Global Cancer Trial Database for Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Official Title: A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors

Study ID: NCT03108131

Conditions

Skin Squamous Cell Carcinoma

Appendix Adenocarcinoma

Rare Lesion

Locally Advanced Malignant Neoplasm

Locally Advanced Skin Squamous Cell Carcinoma

Metastatic Malignant Neoplasm

Metastatic Skin Squamous Cell Carcinoma

Metastatic Small Intestinal Adenocarcinoma

Rare Neoplastic Syndrome

Refractory Malignant Neoplasm

Stage IV Small Intestinal Adenocarcinoma AJCC v8

Unresectable Malignant Neoplasm

Interventions

Atezolizumab

Cobimetinib

Study Description

Brief Summary: This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.

Detailed Description: PRIMARY OBJECTIVE: I. To evaluate the efficacy of cobimetinib plus atezolizumab (COTEZO) in cohorts of advanced rare tumors using objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. SECONDARY OBJECTIVES: I. To determine progression-free survival (PFS) on COTEZO in cohorts of advanced rare tumors per RECIST v1.1 and immune-related (ir)RECIST. II. To determine overall survival (OS) on COTEZO in cohorts of advanced rare tumors. III. To determine disease control rate (DCR) and duration of response (DOR) on COTEZO in cohorts of advanced rare tumors per RECIST v1.1 and irRECIST. IV. To determine objective response rate (ORR) per immune-related RECIST criteria. V. To determine safety profile and adverse events encountered by patients with advanced rare tumors treated with COTEZO. VI. To collect and bank tumor tissue and peripheral blood for future correlative analyses from patients with advanced rare tumors treated with COTEZO. OUTLINE: Participants receive cobimetinib orally (PO) once daily (QD) on days 1-21 and atezolizumab intravenously (IV) over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants followed up every 3 months thereafter.